Nuclear medicine physician

Last updated

Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, [1] [2] are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. [3] [4] [5] In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.

Contents

History

In 1896, Henri Becquerel discovered radioactivity. [6] It was only a little over a quarter of a century (1925) until the first radioactive tracer study in animals was performed by George de Hevesy, and the next year (1926) the first diagnostic tracer study in humans was performed by Herman Blumgart and Otto Yens. [7]

Some of the earliest applications of radioisotopes were therapy of hematologic malignancies and therapy of both benign and malignant thyroid disease. In the 1950s radioimmunoassay was developed by Solomon Berson and Rosalyn Yalow. Dr. Yalow was co-winner of the 1977 Nobel Prize in Physiology or Medicine (Dr. Berson had already died so was not eligible). Radioimmunoassay was used extensively in clinical medicine but more recently has been largely replaced by non-radioactive methods.

In 1950, human imaging of both gamma and positron emitting radioisotopes was performed. Benedict Cassen's work with a directional probe lead to the development of the first imaging with a rectilinear scanner. [8] Gordon Brownell developed the first positron scanner. [9] In the same decade (1954) the Society of Nuclear Medicine (SNM) was organized in Spokane, Washington (US), [10] and (1958) Hal Anger developed the gamma scintillation camera, [11] which could image a whole region at the same time.

Initial introduction of radioisotopes into medicine required individuals to acquire of a considerable background information which was foreign to their medical training. Often a particular application drove the introduction of radioisotopes into a health care facility. As other applications developed the physician or group that had developed knowledge of and experience with radioisotopes usually provided the new service. Consequently, the radioisotope service found homes in several established specialties – commonly in radiology due to an interest in imaging, in pathology (clinical pathology) due to an interest in radioimmunoassay, and in endocrinology due to the early application of 131I to thyroid disease. [12]

Nuclear medicine became widespread and there was a need to develop a new specialty. In the United States, the American Board of Nuclear Medicine was formed in 1972. [13] At that time, the specialty include all of the uses of radioisotopes in medicine – radioimmunoassay, diagnostic imaging, and therapy. As use of and experience with radioisotopes became more widespread in medicine, radioimmunoassay generally transferred from nuclear medicine to clinical pathology. Today, nuclear medicine is based on the use of the tracer principle applied to diagnostic imaging and therapy.

Practice

Procedures

Instrumentation

Most radionuclides give off gamma-rays when they decay. A 2-dimensional image of the radionuclide distribution can be made with a gamma camera, often called an Anger scintillation camera after its inventor, Hal Anger.
Multiple planar images taken from different angles around a patient can be reconstructed to form a stack of cross-sectional, tomographic images.
Some isotopes emit positrons (the anti-matter equivalent of an electron) when they decay. The positrons travel a short distance in tissue and then annihilate with an electron giving off two nearly back-to-back gamma rays. Positron emission tomography takes advantage of these back-to-back gamma rays to localize the distribution of the radioisotopes.
The advantage of nuclear medicine is that it provides molecular and physiologic information, but it is relatively poor at providing anatomic information and the resolution is relatively poor. In recent years, instruments have been developed which allow both radioisotope and anatomic imaging. Most widespread are PET/CT scanners combining PET and computed tomography. Increasingly common are SPECT/CT scanners. Instruments combining PET with magnetic resonance, PET/MRI, are starting to be used.
Non-imaging instruments are used for measuring radioisotope doses, for counting samples, for measuring thyroid uptake of radioiodine, for measuring sentinel lymph node uptake during mastectomy procedures to and for radiation safety.

Training

In the United States, the Accreditation Council for Graduate Medical Education (ACGME) and the American Osteopathic Association Bureau of Osteopathic Specialists (AOABOS) accredit nuclear medicine residency programs, and the American Board of Nuclear Medicine (ABNM) and the American Osteopathic Board of Nuclear Medicine (AOBNM) certify nuclear medicine physicians. After completing medical school, a post-graduate clinical year is followed by three years of nuclear medicine residency. A common alternate path for physicians who have completed a radiology residency is a one-year residency in nuclear medicine, leading to sub-specialty certification by the American Board of Radiology. A less common path for physicians who have completed another residency is a two-year residency in nuclear medicine. [15]

Other professionals

Nuclear medicine procedures are performed by Nuclear Medicine Radiographers, [16] who require extensive training both in underlying principles (physics, instrumentation) but also in the clinical applications. Nursing support, especially in the hospital setting, is valuable, but may be shared with other services. Nuclear medicine is a technology embedded specialty depending upon a large number of non-physician professional, including medical physicists, health physicists, radiobiologists, radiochemists, and radiopharmacists.

Residency trained nuclear medicine physicians have the most extensive training and highest level of certification, including all aspects of diagnosis and radionuclide therapy. However, current U.S. regulations do not prohibit other physicians from interpreting nuclear medicine studies and perform radionuclide therapy. Radiologists who are not sub-specialty trained in the specialty, nonetheless often limit their practice to practicing nuclear medicine. Some cardiologists, especially non-invasive cardiologists, will interpret diagnostic cardiology studies including nuclear medicine studies. Radiation oncologists perform all forms of radiation therapy, sometimes including radionuclide therapy. Some endocrinologists treat hyperthyroidism and thyroid cancer with 131I. The mix of physicians rendering nuclear medicine services varies both between different countries and within a single country.

See also

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.

<span class="mw-page-title-main">Radiology</span> Branch of medicine

Radiology is the medical specialty that uses medical imaging to diagnose diseases and guide their treatment, within the bodies of humans and other animals. It began with radiography, but today it includes all imaging modalities, including those that use no ionizing electromagnetic radiation, as well as others that do, such as computed tomography (CT), fluoroscopy, and nuclear medicine including positron emission tomography (PET). Interventional radiology is the performance of usually minimally invasive medical procedures with the guidance of imaging technologies such as those mentioned above.

Medical physics deals with the application of the concepts and methods of physics to the prevention, diagnosis and treatment of human diseases with a specific goal of improving human health and well-being. Since 2008, medical physics has been included as a health profession according to International Standard Classification of Occupation of the International Labour Organization.

<span class="mw-page-title-main">Single-photon emission computed tomography</span> Nuclear medicine tomographic imaging technique

Single-photon emission computed tomography is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera, but is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.

<span class="mw-page-title-main">Nuclear medicine</span> Medical specialty

Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound - the ligand. The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.

<span class="mw-page-title-main">Scintigraphy</span> Diagnostic imaging test in nuclear medicine

Scintigraphy, also known as a gamma scan, is a diagnostic test in nuclear medicine, where radioisotopes attached to drugs that travel to a specific organ or tissue (radiopharmaceuticals) are taken internally and the emitted gamma radiation is captured by gamma cameras, which are external detectors that form two-dimensional images in a process similar to the capture of x-ray images. In contrast, SPECT and positron emission tomography (PET) form 3-dimensional images and are therefore classified as separate techniques from scintigraphy, although they also use gamma cameras to detect internal radiation. Scintigraphy is unlike a diagnostic X-ray where external radiation is passed through the body to form an image.

<span class="mw-page-title-main">Iodine-131</span> Isotope of iodine

Iodine-131 is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission. See fission product yield for a comparison with other radioactive fission products. 131I is also a major fission product of uranium-233, produced from thorium.

<span class="mw-page-title-main">Isotopes of iodine</span> Nuclides with atomic number of 53 but with different mass numbers

There are 37 known isotopes of iodine (53I) from 108I to 144I; all undergo radioactive decay except 127I, which is stable. Iodine is thus a monoisotopic element.

<span class="mw-page-title-main">Radioisotope renography</span>

Radioisotope renography is a form of medical imaging of the kidneys that uses radiolabelling. A renogram, which may also be known as a MAG3 scan, allows a nuclear medicine physician or a radiologist to visualize the kidneys and learn more about how they are functioning. MAG3 is an acronym for mercapto acetyl tri glycine, a compound that is chelated with a radioactive element – technetium-99m.

Iodine-123 (123I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2230 hours; the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV. In medical applications, the radiation is detected by a gamma camera. The isotope is typically applied as iodide-123, the anionic form.

Abass Alavi is an Iranian-American physician-scientist specializing in the field of molecular imaging, most notably in the imaging modality of positron emission tomography (PET). In August 1976, he was part of the team that performed the first human PET studies of the brain and whole body using the radiotracer [18F]Fluorodeoxyglucose (FDG). Alavi holds the position of Professor of Radiology and Neurology, as well as Director of Research Education in the Department of Radiology at the University of Pennsylvania. Over a career spanning five decades, he has amassed over 2,300 publications and 60,000 citations, earning an h-index of 125 and placing his publication record in the top percentile of scientists.

<span class="mw-page-title-main">Iobenguane</span> Chemical compound

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter norepinephrine (noradrenaline), typically used as a radiopharmaceutical. It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments.

Perfusion is the passage of fluid through the lymphatic system or blood vessels to an organ or a tissue. The practice of perfusion scanning is the process by which this perfusion can be observed, recorded and quantified. The term perfusion scanning encompasses a wide range of medical imaging modalities.

The American Board of Nuclear Medicine (ABNM) certifies physicians as specialists in the practice of nuclear medicine. Diplomates of the ABNM are called nuclear medicine physicians. The ABNM is one of the 24 member boards of the American Board of Medical Specialties (ABMS).

<span class="mw-page-title-main">Cho Zang-hee</span> South Korean neuroscientist (born 1936)

Zang-Hee Cho is a Korean neuroscientist who developed the first Ring-PET scanner and the scintillation detector BGO. More recently, Cho developed the first PET-MRI fusion molecular imaging device for neuro-molecular imaging.

<span class="mw-page-title-main">Radiopharmaceutical</span> Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

Preclinical or small-animal Single Photon Emission Computed Tomography (SPECT) is a radionuclide based molecular imaging modality for small laboratory animals. Although SPECT is a well-established imaging technique that is already for decades in use for clinical application, the limited resolution of clinical SPECT (~10 mm) stimulated the development of dedicated small animal SPECT systems with sub-mm resolution. Unlike in clinics, preclinical SPECT outperforms preclinical coincidence PET in terms of resolution and, at the same time, allows to perform fast dynamic imaging of animals.

<span class="mw-page-title-main">Siroos Mirzaei</span> Iranian specialist in Nuclear Medicine (born 1963)

Siroos Mirzaei is an Iranian specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna. Mirzaei is well known for his scientific work on torture diagnostics with molecular imaging methods.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

References

  1. ↑ PET/CT with contrast
  2. ↑ Radiology (ACR), Radiological Society of North America (RSNA) and American College of. "Professions in Nuclear Medicine". Radiologyinfo.org. Retrieved 2023-10-23.
  3. ↑ Wagner Henry N. (2006), A Personal History of Nuclear Medicine. Springer. ISBN   978-1-85233-972-2
  4. ↑ National Atomic Museum
  5. ↑ Potchen EJ: Reflections on the early years of nuclear medicine. Radiology 2000; 214:623-624. PMID   10715020
  6. ↑ Blaufox MD: Becquerel and the discovery of radioactivity: Early concepts. Semin Nucl Med 1996; 26:145–154. PMID   8829275
  7. ↑ Patton DD: The birth of nuclear medicine instrumentation: Blumgart and Yens, 1925. J Nucl Med 2003; 44:1362. PMID   12902429
  8. ↑ Blahd WH: Ben Cassen and the development of the rectilinear scanner. Semin Nucl Med 1996; 26:165–170. PMID   8829277.
  9. ↑ A History of positron imaging
  10. ↑ Harris CC: The formation and evolution of the society of nuclear medicine. Semin Nucl Med 1996;26:180–190. PMID   8829279
  11. ↑ Gottschalk A: The early years with Hal Anger. Semin Nucl Med 1996; 26:171–179. PMID   8829278
  12. ↑ Becker DV, Sawin CT: Radioiodine and thyroid disease: The beginning. Semin Nucl Med 1996; 26:155–164. PMID   8829276
  13. ↑ Ross JF: A history of the American Board of Nuclear Medicine. Semin Nucl Med. 1996 Jul;26(3):191–193. PMID   8829280.
  14. ↑ PET center of excellence
  15. ↑ ABNM brochure Archived 2007-07-01 at the Wayback Machine
  16. ↑ nuclear medicine technologists
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.